Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biodesix (BDSX) Receivables - Net (2019 - 2025)

Historic Receivables - Net for Biodesix (BDSX) over the last 7 years, with Q3 2025 value amounting to $12.7 million.

  • Biodesix's Receivables - Net rose 5771.53% to $12.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.7 million, marking a year-over-year increase of 5771.53%. This contributed to the annual value of $8.6 million for FY2024, which is 1203.28% up from last year.
  • According to the latest figures from Q3 2025, Biodesix's Receivables - Net is $12.7 million, which was up 5771.53% from $7.5 million recorded in Q2 2025.
  • In the past 5 years, Biodesix's Receivables - Net ranged from a high of $18.4 million in Q1 2021 and a low of $2.8 million during Q3 2021
  • Its 5-year average for Receivables - Net is $7.1 million, with a median of $5.8 million in 2023.
  • In the last 5 years, Biodesix's Receivables - Net tumbled by 7945.23% in 2022 and then soared by 14588.49% in 2024.
  • Biodesix's Receivables - Net (Quarter) stood at $3.7 million in 2021, then skyrocketed by 38.54% to $5.1 million in 2022, then skyrocketed by 51.61% to $7.7 million in 2023, then increased by 12.03% to $8.6 million in 2024, then soared by 47.32% to $12.7 million in 2025.
  • Its last three reported values are $12.7 million in Q3 2025, $7.5 million for Q2 2025, and $7.6 million during Q1 2025.